In addition to establishing drug safety and efficacy under existing regulations, sponsors are increasingly required to develop comprehensive risk management programs, including risk assessment and minimization, also known as Risk Evaluation Mitigation Strategies (REMS). How pharmaceutical risk management is implemented can have considerable ramifications for labeling, regulatory decisions, legal protection, intellectual property, enforcement, marketing, and company reputation.
Pinney Associates teams have the knowledge and resources to help clients find the most appropriate path to the marketplace by assessing the scientific and policy environment, and evaluate individual compounds and formulations within this context. We assess risks including drug-induced adverse events, those resulting from accidental use, misuse, abuse, and diversion, as well as potential regulatory hurdles, and down the road – litigation risks. We work with clients to develop comprehensive risk management that will be reassuring to regulators, facilitate commercial goals, and protect the franchise long into the future.
Our experts are recognized leaders in pharmaceutical risk management and have participated in dialogue and collaborated with the Food and Drug Administration, Drug Enforcement Administration, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Congress, the Food and Drug Law Institute, and the College on Problems of Drug Dependence.
Specific services Pinney Associates can provide in the risk management arena include: